3i Infotech has received an IT services contract worth Rs 37.05 crore from Hindustan Petroleum Corporation (HPCL), for providing Facility Management Services (FMS) across HPCL locations for three years.
The engagement involves providing IT services across HPCL's Corporate R&D Centre, Visakh Refinery, Head Office, Zones, ISC and multiple PAN India locations. The scope includes skilled manpower support, desktop and endpoint support, printer and scanner support, server support, VMS endpoint support, travel assistance and related IT infrastructure support services.
Under this engagement, company will support HPCL's distributed IT operations through managed infrastructure services, enabling continuity, operational efficiency and reliable support across critical business locations.
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of Bayer Healthcare Pharmaceuticals Inc. (Bayer).
Larotrectinib is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: a) have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, b) are metastatic or where surgical resection is likely to result in severe morbidity, and c) have no satisfactory alternative treatments or that have progressed following treatment.
Larotrectinib Capsules, 25 mg and 100 mg, have an estimated market size of US$ 91 million for twelve months ending March 2026 according to IQVIA.